Indo Nippon: A New Sun Rises To Link Indian And Japanese Drug Firms
This article was originally published in PharmAsia News
Executive Summary
In search of business opportunities, several Indian and Japanese drug makers have come under one roof to identify joint projects. The architect of the new initiative is Satish Khanna, an industry veteran who has seen successes with similar ventures in the past.
You may also be interested in...
India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.